Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population

摘要: Background and objective:  Individuals with pulmonary arterial hypertension (PAH) experience severely impaired quality of life. A disease-specific patient reported outcome measure for PAH (the Cambridge Pulmonary Hypertension Outcome Review—CAMPHOR) has recently been developed validated in the UK, USA Canada. It demonstrated reliability validity populations these countries. The aim this study was to assess CAMPHOR an Australian New Zealand (NZ) population. Methods:  Semistructured interviews were conducted a cohort 15 patients (aged 68.9 ± 10.0 years; 11 women) determine relevance ensure terminology language used understandable appropriate our population. test–retest reliability, internal consistency construct then examined NZ population (n = 61, aged 56.9 ± 14.5 years; 48 women). Results:  Data from confirmed that is use three scales (symptoms, activity limitations life) had excellent (correlation coefficients (rs) = 0.86–0.94, P < 0.01) (Cronbach's alpha coefficients = 0.89–0.92). also ability distinguish between individuals who differed according World Health Organisation functional class. Conclusions:  We have shown be valid reliable recommend its clinical practice.